Daniel Torrent: A New Path for ‘No-Option’ Patients – TADV vs Standard of Care in CLTI
Daniel Torrent, Vascular Surgeon at Longstreet Clinic, shared a post on LinkedIn about a recent article by Mounika Naidu Boya et al, published in JVS:
“‘No-option’ CLTI doesn’t have to mean ‘no hope’.
The results of this systematic review and meta-analysis on TADV (Transcatheter Arterialization of Deep Veins) aren’t surprising if you’ve been paying attention to this world. It’s still nice to see it pulled together and peer reviewed.
The most striking stat? Survival. Even though the patients undergoing TADV have similar medical issues to those that don’t, there’s a fairly startling difference in mortality. Saving limbs saves lives.
Interpreting Patency: Patency isn’t on the infographic because there isn’t anything to compare to on the Standard of Care (SoC) cohort which comes from a natural history study. However, generally, primary and primary-assisted patency is less than 50% at six months. Despite this, the limb preservation statistics are wonderful. This procedure works differently than a standard revascularization.
Optimizing for Success: I’ve been impressed with how this procedure has been implemented as well. It wasn’t just thrown out into the market. It’s been a thoughtful rollout with mandatory training and program support. Beyond training on the procedure, I’ve had help on training the ultrasound team for pre-operative and post-operative evaluations. CLTI is a process where the full spectrum of care matters.”
Title: Evidence for transcatheter arterialization of deep veins in poor-option chronic limb-threatening ischemia: A systematic review and meta-analysis
Authors: Mounika Naidu Boya, Isabella Ferlini Cieri, Adriana A. Rodriguez Alvarez, Shiv Patel, Peter A. Schneider, Daniel Clair, Mehdi H. Shishehbor, Anahita Dua
Read the Full Article on Society for Vascular Surgery.

Find more posts featuring Daniel Torrent on Hemostasis Today.
-
Jul 14, 2026, 19:35Daratumumab in Difficult-to-Treat iTTP: Updated Results from the International DarTTP Study
-
Jul 14, 2026, 17:1610 Posts Not To Miss from ISTH 2026, Part 3
-
Jul 14, 2026, 15:27Dianne E Van Der Wal: Celebrating Scientific Contributions at ISTH 2026
-
Jul 14, 2026, 15:13Alfonso Tafur: RIETE Registry Analysis Supports More Equitable Approaches to VTE Care
-
Jul 14, 2026, 15:03Heghine Khachatryan: Phase III Trial Results Support BAFF-R Inhibition in Corticosteroid-Refractory ITP
-
Jul 14, 2026, 14:51Nathan Connell: ISTH 2026 Highlights the Power of Lifelong Collaboration
-
Jul 14, 2026, 14:42Wolfgang Miesbach: VOYAGER1 Highlights Progress Toward Injection-Free Care in Hemophilia A
-
Jul 14, 2026, 12:08Elvira Grandone: Finding the Right LMWH Dose for Pregnant Patients Suffering From DVT
-
Jul 14, 2026, 12:05Eloïse Laouenan: From Washington to Paris – Join GETBO at ISTH 2026